Disseminated Intravascular Coagulation — Treat Cause and Support

Key Points

• DIC is always secondary to another disease process, so treating the cause is the central intervention.
• A normal fibrinogen does not exclude sepsis-associated DIC; trends matter.
• Platelet count, PT/INR, aPTT, fibrinogen, and D-dimer should be interpreted together and repeated serially.
• Do not transfuse plasma or platelets solely to normalize abnormal laboratory values in a stable nonbleeding patient.
• Active bleeding or an urgent invasive procedure changes component-transfusion thresholds.
• Fibrinogen replacement is important when clinically significant bleeding coexists with hypofibrinogenemia.
• Heparin is reserved for selected thrombosis-predominant DIC rather than routine use in every case.
• Suspected acute promyelocytic leukemia requires immediate ATRA and hematology involvement.

Algorithm

1. Identify and treat the precipitating infection, trauma, obstetric event, malignancy, or other trigger.
2. Obtain and trend CBC/platelets, PT/INR, aPTT, fibrinogen, D-dimer, renal/liver function, lactate, and smear.
3. Control bleeding sources and correct shock, hypothermia, acidosis, and hypocalcemia.
4. Give platelets for active bleeding/procedure-related thrombocytopenia according to severity and protocol.
5. Give FFP for active bleeding with clinically important coagulation-factor depletion.
6. Replace fibrinogen with cryoprecipitate or fibrinogen concentrate when low in a bleeding patient.
7. Use heparin only when thrombosis predominates or another strong indication exists and bleeding risk is acceptable.
8. Continue serial laboratory and clinical reassessment until the underlying driver is controlled and coagulation stabilizes.

Clinical Synopsis & Reasoning

DIC is a dynamic syndrome rather than a single laboratory threshold. Sepsis-associated DIC can initially have normal or elevated fibrinogen because fibrinogen is an acute-phase reactant, so a falling fibrinogen trend can be more informative than one normal value. Platelets often fall, D-dimer rises markedly, and PT may prolong. Schistocytes can appear but are usually less prominent than in primary thrombotic microangiopathies. Clinical manifestations range from oozing at lines and mucosal bleeding to purpura, acral ischemia, venous or arterial thrombosis, renal failure, respiratory failure, and shock.

Common precipitants include severe infection, placental abruption, amniotic fluid embolism, retained dead fetus in uncommon prolonged settings, postpartum hemorrhage, major trauma, burns, metastatic adenocarcinoma, acute promyelocytic leukemia, transfusion reaction, pancreatitis, and vascular catastrophes. The differential includes TTP/HUS, severe liver failure, massive transfusion dilution, HIT, vitamin K deficiency, and primary hyperfibrinolysis. The clinical context and pattern of laboratory change distinguish these entities.

Use a validated scoring framework such as the ISTH overt-DIC score when helpful, but do not delay treatment of a bleeding septic or obstetric patient while calculating a score. Repeat coagulation testing frequently in evolving DIC because values can change over hours. Viscoelastic testing can supplement conventional tests in trauma and obstetric hemorrhage where available, particularly for targeted fibrinogen and component therapy.

Treatment Strategy & Disposition

Definitive treatment is control of the underlying cause: antibiotics and source control for sepsis, delivery and hemorrhage control for obstetric catastrophe, surgery or hemostatic resuscitation for trauma, and disease-specific therapy for malignancy. Hemostatic replacement cannot overcome ongoing uncontrolled tissue-factor activation by itself. Support oxygenation, perfusion, temperature, calcium, acid-base status, and organ function because hypothermia, acidosis, and hypocalcemia worsen coagulopathy.

Give platelets, plasma, and fibrinogen replacement according to bleeding, planned invasive procedures, and laboratory deficits. In a nonbleeding patient, prophylactic platelet transfusion is generally avoided unless the count is extremely low or bleeding risk is high. With active bleeding or an invasive procedure, many guidance pathways target platelets at least around 50 x 10^9/L. FFP is useful when active bleeding accompanies prolonged PT/aPTT and factor depletion. Cryoprecipitate or fibrinogen concentrate is used for clinically important hypofibrinogenemia, commonly targeting fibrinogen above roughly 1.5 g/L, with higher targets used in major obstetric hemorrhage according to protocol.

Therapeutic heparin is not routine for bleeding-predominant acute DIC but may be appropriate when thrombosis predominates, such as purpura fulminans, acral ischemia, or another clear VTE indication, and bleeding risk is acceptable. VTE prophylaxis is still considered in stable nonbleeding critically ill patients. Acute promyelocytic leukemia is a special emergency: start all-trans retinoic acid immediately when APL is suspected and aggressively support fibrinogen and platelets with hematology guidance because catastrophic intracranial or pulmonary hemorrhage can occur early.

Epidemiology / Risk Factors

• Sepsis is one of the most common causes of acute DIC in critical care.
• Major trauma and obstetric emergencies are important rapidly evolving causes.
• Certain adenocarcinomas can cause chronic compensated or thrombosis-predominant DIC.
• Acute promyelocytic leukemia has a particularly strong association with severe coagulopathy.
• DIC incidence rises with severity of the underlying systemic insult.

Investigations

Product Targets (Adults)

Pharmacology

Prognosis / Complications

• Outcome is driven largely by the underlying disease and degree of organ failure.
• Rapid source control and reversal of shock can normalize coagulation abnormalities as the trigger resolves.
• Intracranial, pulmonary, and gastrointestinal hemorrhage are major causes of death in severe bleeding-predominant DIC.
• Microvascular thrombosis contributes to kidney, liver, respiratory, skin, and neurologic injury.
• Persistent DIC despite supportive transfusion indicates ongoing uncontrolled disease and requires renewed source investigation.

Patient Education / Counseling

• Explain that DIC is a complication of another serious illness rather than an isolated blood disorder.
• Patients recovering from DIC should understand the underlying trigger and its recurrence risk.
• Report new bleeding, extensive bruising, black stools, severe headache, cold or painful digits, or recurrent infection symptoms urgently.
• After obstetric DIC, arrange postpartum anemia, thrombosis, and obstetric follow-up as indicated.
• Cancer-associated DIC requires ongoing hematology/oncology treatment even after coagulation tests improve.
• Medication plans for anticoagulants or antiplatelet drugs should be explicitly reviewed before discharge.

Notes

Blood-product therapy in DIC is clinical, not cosmetic. The goal is to support hemostasis in a bleeding or procedural patient while the underlying trigger is being controlled, not to make every coagulation value normal.

Fibrinogen deserves special attention in obstetric and massive-hemorrhage DIC because it can fall rapidly, while in sepsis a normal or high initial fibrinogen can coexist with active DIC.

References

1. British Society for Haematology DIC Guidance — Link
2. American Society of Hematology Blood Review on DIC — Link